Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Cocks

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Head & Neck|July 7, 2020
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancerJammbe Z Musoro, Corneel Coens, Susanne Singer, et al.
Health Technology Assessment (Winchester, England)|April 13, 2017
Youth social behaviour and network therapy (Y-SBNT): adaptation of a family and social network intervention for young people who misuse alcohol and drugs - a randomised controlled feasibility trialJudith Watson, Paul Toner, Ed Day, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survivalNaveen S Vasudev, Janet E Brown, Sarah R Brown, et al.
Ejhaem|July 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL RegistryJeff P Sharman, Kim Cocks, Chadi Nabhan, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2022
Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancerKim Cocks, Jane R Wells, Colin Johnson, et al.
Neuro-Oncology|February 18, 2021
Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patientsLinda Dirven, Jammbe Z Musoro, Corneel Coens, et al.
British Journal of Haematology|January 15, 2011
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemiaPeter Hillmen, Dena R Cohen, Kim Cocks, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 13, 2013
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24Fabio Efficace, Michele Baccarani, Massimo Breccia, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple MyelomaA Keith Stewart, Meletios A Dimopoulos, Tamás Masszi, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Head & Neck|July 7, 2020
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancerJammbe Z Musoro, Corneel Coens, Susanne Singer, et al.
Health Technology Assessment (Winchester, England)|April 13, 2017
Youth social behaviour and network therapy (Y-SBNT): adaptation of a family and social network intervention for young people who misuse alcohol and drugs - a randomised controlled feasibility trialJudith Watson, Paul Toner, Ed Day, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survivalNaveen S Vasudev, Janet E Brown, Sarah R Brown, et al.
Ejhaem|July 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL RegistryJeff P Sharman, Kim Cocks, Chadi Nabhan, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2022
Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancerKim Cocks, Jane R Wells, Colin Johnson, et al.
Neuro-Oncology|February 18, 2021
Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patientsLinda Dirven, Jammbe Z Musoro, Corneel Coens, et al.
British Journal of Haematology|January 15, 2011
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemiaPeter Hillmen, Dena R Cohen, Kim Cocks, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 13, 2013
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24Fabio Efficace, Michele Baccarani, Massimo Breccia, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple MyelomaA Keith Stewart, Meletios A Dimopoulos, Tamás Masszi, et al.
Pageof 9